Get the Stockscreener App
20.85
5.09%
1.01
Enliven Therapeutics Inc stock is traded at $20.85, with a volume of 830.39K.
It is up +5.09% in the last 24 hours and down -3.29% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$19.84
Open:
$19.99
24h Volume:
830.39K
Relative Volume:
1.72
Market Cap:
$1.24B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-11.03
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
+3.12%
1M Performance:
-3.29%
6M Performance:
-4.36%
1Y Performance:
-8.95%
1-Day Range:
$19.62
$21.07
1-Week Range:
$19.01
$21.07
52-Week Range:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
20.85 | 1.17B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
How to forecast Enliven Therapeutics Inc. trends using time series2025 Fundamental Recap & Consistent Profit Alerts - Newser
Enliven Therapeutics Inc. Price Targets Raised After ReboundTrade Volume Report & Fast Entry High Yield Tips - kangso.co.kr
Can Enliven Therapeutics Inc. Escape Recent Bear ChannelJuly 2025 Retail & Weekly Setup with High ROI Potential - thegnnews.com
Reversal indicators forming on Enliven Therapeutics Inc. stockJuly 2025 PreEarnings & Growth-Oriented Investment Plans - Newser
Should you wait for a breakout in Enliven Therapeutics Inc.2025 Macro Impact & Consistent Income Trade Ideas - Newser
Combining price and volume data for Enliven Therapeutics Inc.July 2025 Technicals & Daily Entry Point Alerts - Newser
Chart overlay techniques for tracking Enliven Therapeutics Inc.Forecast Cut & Daily Risk Controlled Trade Plans - Newser
How to integrate Enliven Therapeutics Inc. into portfolio analysis toolsPortfolio Value Report & Fast Moving Stock Trade Plans - Newser
Applying chart zones and confluence areas to Enliven Therapeutics Inc.2025 Market Trends & High Accuracy Swing Entry Alerts - Newser
Is Enliven Therapeutics Inc. stock bottoming outGDP Growth & Stepwise Trade Execution Plans - Newser
What MACD signals say about Enliven Therapeutics Inc.Weekly Trade Summary & AI Powered Buy and Sell Recommendations - Newser
Published on: 2025-08-19 14:05:08 - Newser
Analyzing Enliven Therapeutics Inc. with risk reward ratio chartsQuarterly Growth Report & AI Powered Market Entry Ideas - Newser
How to use Fibonacci retracement on Enliven Therapeutics Inc.2025 Price Targets & AI Forecast Swing Trade Picks - Newser
Technical signs of recovery in Enliven Therapeutics Inc.Quarterly Growth Report & Weekly High Return Opportunities - Newser
Analyzing net buyer seller activity in Enliven Therapeutics Inc.2025 Market Trends & AI Forecasted Entry and Exit Points - Newser
Is Enliven Therapeutics Inc. trending in predictive chart modelsWatch List & Verified Momentum Stock Alerts - Newser
Enliven Therapeutics Reports Positive Trial Results and Strong Financials - MSN
RSI Suggests Rebound May Be Near in Enliven Therapeutics Inc.2025 Investor Takeaways & Smart Allocation Stock Tips - classian.co.kr
Using AI based signals to follow Enliven Therapeutics Inc.Weekly Risk Report & AI Forecast Swing Trade Picks - Newser
Multi factor analysis applied to Enliven Therapeutics Inc.2025 Market Outlook & Risk Managed Investment Signals - Newser
What is Lifesci Capital’s Estimate for ELVN Q3 Earnings? - Defense World
Will Enliven Therapeutics Inc. stock go up in YEARBreakout Watch & Growth-Oriented Investment Plans - thegnnews.com
Using economic indicators to assess Enliven Therapeutics Inc. potentialJuly 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
Can Enliven Therapeutics Inc. rally from current levels2025 Investor Takeaways & Verified Trade Idea Suggestions - Newser
Can volume confirm reversal in Enliven Therapeutics Inc.July 2025 Earnings & Smart Money Movement Alerts - Newser
Will Enliven Therapeutics Inc. stock split in the near futureRate Hike & AI Powered Buy and Sell Recommendations - Newser
Sectors Driving Future Growth for Enliven Therapeutics Inc. Stock2025 Technical Overview & High Accuracy Trade Alerts - Newser
Is Enliven Therapeutics Inc. a Top Dividend Stock to Watch in 2025Inflation Watch & Technical Pattern Alert System - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityGap Up & Entry Point Strategy Guides - Newser
Why Enliven Therapeutics Inc. stock attracts strong analyst attentionTrade Analysis Summary & Comprehensive Market Scan Reports - thegnnews.com
Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating - TipRanks
We're Not Very Worried About Enliven Therapeutics' (NASDAQ:ELVN) Cash Burn Rate - Yahoo Finance
Real time social sentiment graph for Enliven Therapeutics Inc.Trade Analysis Report & Expert Curated Trade Setup Alerts - Newser
Enliven Therapeutics: Cash runway could fund ops into 2029 - BizWest
Enliven Therapeutics: Strong Financial Health and Promising CML Treatment Drive Buy Rating - TipRanks
Enliven Therapeutics shares fall 1.58% intraday after reporting positive Phase 1 clinical trial data for ELVN-001 in CML. - AInvest
BTIG reiterates Buy rating on Enliven Therapeutics stock with $45 target - Investing.com Canada
BTIG reiterates Buy rating on Enliven Therapeutics stock with $45 target By Investing.com - Investing.com South Africa
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Aug 19 '25 |
Sale |
19.62 |
5,000 |
98,118 |
947,688 |
| Kintz Samuel | PRESIDENT AND CEO |
Aug 18 '25 |
Sale |
20.02 |
10,393 |
208,106 |
929,999 |
| Kintz Samuel | PRESIDENT AND CEO |
Aug 19 '25 |
Sale |
20.00 |
590 |
11,800 |
929,409 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):